Skip to main content
SpringerLink
Log in

[18F]Fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer

  • Published:
European Journal of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Seventeen patients with advanced breast cancer were imaged with a specially collimated gamma camera to study tumor uptake of 2-[18F]-fluoro-2-deoxy-D-glucose (FDG) before and during therapy. Fourteen patients (82%) showed increased FDG accumulation in metastatic tumors, 6/8 (75%) of axillary, supra or infraclavicular metastatic lymph nodes were detectable. In one of these cases, FDG imaging was the first method to identify axillary metastasis causing nerve compression. Also, pulmonary and liver metastases could be imaged with FDG; both in two patients. The intra individual variability in uptake was considerable in bone metastases, and some lesions remained FDG negative:99mTc-DPD was superior in detecting bone disease. Bone metastases of the osteolytic or mixed type were better visualized than sclerotic ones. Ten patients were reimaged later to assess the effect of therapy on FDG uptake. Increased uptake was associated with clinical progression, while unchanged or diminished uptake did not predict the course of disease as reliably. This study indicates that FDG can be used to image breast cancer metastases. FDG may be valuable in monitoring treatment response, but positron emission tomography (PET) would probably be more appropriate than planar imaging for this purpose.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Abe Y, Matsuzawa T, Fujiwara T, Fukuda H, Itoh M, Yamada K, Yamaguchi K, Sato T, Ido T (1986) Assessment of radiotherapeutic effects on experimental tumors using18F-2-fluoro-2-deoxy-D-glucose. Eur J Nucl Med 12:325–328

    Google Scholar 

  • Ahonen A, Paul R, Aho A, Dean P, Roeda D, Solin O, Virtama P, Ekfors T, Nordman E, Haaparanta M, Wegelius U (1986) Differential diagnosis of bone tumors using fluorodeoxyglucose and three phase99mTc-DPD scanning. In: Schmidt HAE, Ell PJ, Britton KE (eds) Nuclearmedizin. Proc. ENMC. Schattauer, Stuttgart New York, pp 441–443

    Google Scholar 

  • d'Argy R, Paul R, Frankenberg L, Stålnacke CG, Lundqvist H, Kangas L, Halldin C, Någren K, Roeda D, Haaparanta M, Solin O, Långström B (1988) Comparative double-tracer wholebody autoradiography: uptake of11C-,18F-, and3H-labeled compounds in rat tumors. Int J Nucl Med Biol 15:577–585

    Google Scholar 

  • Beaney RP, Lammertsma AA, Jones T, McKenzie CG, Halnan KE (1984) Positron emission tomography for in-vivo measurement of regional blood flow, oxygen utilisation, and blood volume in patients with breast carcinoma. Lancet 1:131–134

    Google Scholar 

  • Bolster JM, Vaalburg W, Paans AMJ, van Dijk TH, Elsinga PH, Zijlstra JB, Piers DA, Mulder NH, Woldring MG, Wynberg H (1986) Carbon-11 labelled tyrosine to study tumor metabolism by positron emission tomography (PET). Eur J Nucl Med 12:321–324

    Google Scholar 

  • Campbell FC, Blamey RW, Elston CW, Morris AH, Nicholson RI, Griffiths K, Haybittle JL (1981) Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet 2:1317–1319

    Google Scholar 

  • Di Chiro G (1986) Positron emission tomography using [18F]fluorodeoxyglucose in brain tumors: a powerful diagnostic and prognostic tool. Invest Radiol 22:360–371

    Google Scholar 

  • Di Chiro G, Hatazawa J, Katz DA, Rizzoli HV, De Michele DJ (1987) Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study. Radiology 164:521–526

    Google Scholar 

  • Fisher ER (1984) The impact of pathology on the biologic, diagnostic, prognostic, and therapeutic considerations in breast cancer. Surg Clin North Am 64:1073–1093

    Google Scholar 

  • Fukuda H, Ito M, Matsuzawa T, Abe Y, Yoshioka S, Kubota K, Kiyosawa M, Hatazawa J, Ito K, Fujiwara T, Yamada K, Ido T (1983) Clinical evaluation of cancer diagnosis with18F-2-deoxy-2-fluoro (18F)-D-glucose. CYRIC annual report 1983:244–249

    Google Scholar 

  • Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP (1978) Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of (18F)2-deoxyglucose. J Nucl Med 19:1154–1161

    Google Scholar 

  • Hayward JL, Carbone PP, Heuson JC, Kumaska S, Segaloff A, Reubens RD (1977) Assessment of response to therapy in advanced breast cancer. Cancer 39:1289–1293

    Google Scholar 

  • Haaparanta M, Bergman J, Solin O, Roeda D (1984) A remotely controlled system for the routine synthesis of18F-2-fluoro-2-deoxy-D-glucose. Nuklearmedizin 21 [Suppl]:823–826

    Google Scholar 

  • Harris JR, Schnitt SJ, Connolly JL, Silen W (1987) Conservative surgery and radiation therapy for early breast cancer. Arch Surg 122:754–755 (editorial)

    Google Scholar 

  • Iosilevsky G, Front D, Bettman L, Hardoff R, Ben-Arieh Y (1985) Uptake of gallium-67 citrate and [2-3H] deoxyglucose in the tumor model, following chemotherapy and radiotherapy. J Nucl Med 26:278–282

    Google Scholar 

  • Joensuu H, Ahonen A (1987) Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med 28:910–914

    Google Scholar 

  • Minn H, Joensuu H, Ahonen A, Klemi P (1988a) Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Cancer 61:1776–1781

    Google Scholar 

  • Minn H, Paul R, Ahonen A (1988b) Evaluation of treatment response to radiotherapy in head and neck cancer with (18F)fluorodeoxyglucose. J Nucl Med 21:1521–1525

    Google Scholar 

  • Mintun MA, Welch MJ, Mathias CJ (1987) Application of 16α-[F-18]-fluoro-17β-estradiol (I) for the assessment of estrogen receptors in human breast carcinoma. J Nucl Med 28 [Suppl.]:561 A:19 (abstr)

    Google Scholar 

  • Nolop KB, Rhodes CG, Brudin LH, Beaney RP, Krausz T, Jones T, Hughes JMB (1987) Glucose utilization in vivo by human pulmonary neoplasms. Cancer 60:2682–2689

    Google Scholar 

  • Patronas NJ, DiChiro G, Brooks RA, DeLaPaz RL Kornblith PL, Smith HH, Rizzoli HV, Kessler RM, Manning RG, Channing M, Wolf AP, O'Connor CM (1982) Work in progress:18F fluorodeoxyglucose and emission tomography in the evaluation of radiation necrosis of the brain. Radiology 144:885–889

    Google Scholar 

  • Paul R, Roeda D, Johansson R, Ahonen A, Haaparanta M, Solin O, Sipilä H (1986) Scintigraphy with [18F]2-fluoro-2-deoxy-D-glucose of cancer patients. Int J Nucl Med Biol 13:7–12

    Google Scholar 

  • Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE (1979) Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18) 2-fluoro-2-deoxy-D-glucose: validation of a method. Ann Neurol 6:371–388

    Google Scholar 

  • Schelstraete K, Simons M, Deman J, Vermeulen FL, Slegers G, Vandecasteele C, Goethals P, De Schryver A (1982) Uptake of13N-ammonia by human tumours as studied by positron emission tomography. Br J Radiol 55:797–804

    Google Scholar 

  • Sokoloff L, Reivich M, Kennedy C, DesRosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M (1977) The (14C) deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28:897–916

    Google Scholar 

  • Som P, Atkins HL, Bandoypadhyay D, Fowler JS, McGregor RR, Matsui L, Oster ZH, Sacker DF, Shiue CY, Turner H, Wan C-N, Wolf AP, Zabinski SV (1980) A fluorinated glucose analog 2-fluoro-2-deoxy-D-glucose (F-18): Nontoxic tracer for rapid tumor detection. J Nucl Med 21:670–675

    Google Scholar 

  • Takahashi H, Yamaguchi K, Wakui A, Maeda S, Kong Yang P, Ito M, Matsuzawa T, Fukuda H, Ido T (1986a) New approach to clinical evaluation of cancer chemotherapy using positron emission tomography with18FDG(2-deoxy-2-[18F] fluoro-D-glucose. Sci Rep Res Inst Tokohu Univ 33:38–43

    Google Scholar 

  • Takahashi H, Maeda S, Yang PK, Wakui A, Ishiwata K, Iwata R, Takahashi T, Ido T (1986b) Changes in growth and18FDG(2-deoxy-2-[18F]fluoro-D-glucose) uptake of rat hepatomas by anticancer drugs. CYRIC Annual Report 1986:195–200

    Google Scholar 

  • UICC (International Union Against Cancer) (1978) TNM classification of malignant tumours. Harmer MH (ed), Third edition, Geneva, pp 47–54

  • Walker RA, Sanderson PR, Day SJ (1986) The utilization of [3H] sugars by non-malignant and malignant human breast. J Pathol 149:173–181

    Google Scholar 

  • Weber MJ (1984) Metabolic and transport alterations in cells transformed by Rous sarcoma virus. In: Knapp WH, Vyska K (eds) Tumor cell physiology and positron emission tomography. Springer, Berlin Heidelberg New York pp 1–9

    Google Scholar 

  • Weinhouse S (1972) Glycolysis, respiration, and anomalous gene expression in experimental hepatoma: G.H.A. Clowes memorial lecture. Cancer Res 32:2007–2016

    Google Scholar 

  • Weisenthal LM, Lippman ME (1985) Clonogenic and nonclonogenic in vitro chemosensitivity assays. Cancer Treat Rep 69:615–632

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiotherapy, University Central Hospital of Turku Turku Medical Cyclotron Project, SF-20520, Turku, Finland

    Heikki Minn

  2. Department of Radiology and Nuclear Medicine, University Central Hospital of Turku Turku Medical Cyclotron Project, SF-20520, Turku, Finland

    Irma Soini

Authors
  1. Heikki Minn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Irma Soini
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Minn, H., Soini, I. [18F]Fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Eur J Nucl Med 15, 61–66 (1989). https://doi.org/10.1007/BF00702620

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00702620

Key words

Search

Navigation